Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman‐Censits, Gopa Iyer, Christof Vulsteke, Se Hoon Park, Sang Joon Shin, Daniel Castellano, Giuseppe Fornarini, Jian‐Ri Li, Mahmut Gümüş, Nataliya Mar, Yohann Loriot, Aude Fléchon, Ignacio Durán, Alexandra Drakaki, Sujata Narayanan, Xuesong Yu, Seema Rao Gorla, Blanca Homet Moreno, Michiel S. van der Heijden

doi:10.1056/nejmoa2312117

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman‐Censits, Gopa Iyer, Christof Vulsteke, Se Hoon Park, Sang Joon Shin, Daniel Castellano, Giuseppe Fornarini, Jian‐Ri Li, Mahmut Gümüş, Nataliya Mar, Yohann Loriot, Aude Fléchon, Ignacio Durán, Alexandra Drakaki, Sujata Narayanan, Xuesong Yu, Seema Rao Gorla, Blanca Homet Moreno, Michiel S. van der Heijden

New England Journal of Medicine · 2024

Read source ↗ All evidence

Summary

Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with a safety profile consistent with that in previous reports. (Funded by Astellas Pharma US and others; EV-302 ClinicalTrials.gov number, NCT04223856.).

Source type: Peer-reviewed study
DOI: 10.1056/nejmoa2312117
Catalogue ID: BFmoef2rp1-pkabwu

Pulse AI · ask about this record

Dig deeper with Pulse AI.

Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.

How does this finding apply in a UK context?→What are the most cited records on this topic?→